Neil T Parkin

This inventor holds 22 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 5 EPO patents. Top assignees: Monogram Biosciences, Inc., Aviron, Medimmune Vaccines, Inc.. Active years: 1997-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Neil T Parkin. Retrieved from https://idiyas.com/inventor/neil-t-parkin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 22 (Patent Applications = 3)

% Patents Active = 86.4

CIPO Patents = 2 (Patent Applications = 8)

EPO Patents = 5 (Patent Applications = 4)

Average Co-Inventor Count = 2.2

ph-index = 8

Forward Citations = 290(Granted Patents)

Location History:

South San Francisco, CA (US) (2005)
Belmont, CA (US) (1997 - 2019)

Company Filing History:

15 out of 52

Monogram Biosciences, Inc.

Medimmune Vaccines, Inc.

Years Active: 1997-2019

Loading Chart...

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10202658 - Methods for determining hypersusceptibility of HIV-1 to non-nucleoside reverse transcriptase inhibitors (2019-02-12),

2. 9841425 - Methods for evaluating viral receptor/co-receptor usage and inhibitors of virus entry using recombinant virus assays (2017-12-12),

3. 9175355 - Methods for determining the presence of antibodies blocking viral infection (2015-11-03),

4. 8637252 - Methods and compositions for determining altered susceptibility of HIV-1 to anti-HIV drugs (2014-01-28),

5. 8178291 - Methods and compositions for determining hypersusceptibility of HIV-1 to non-nucleoside reverse transcriptase inhibitors (2012-05-15),

6. 8071284 - Methods and compositions for determining altered susceptibility of HIV-1 to anti-HIV drugs (2011-12-06),

7. 7993824 - Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors (2011-08-09),

8. 7553618 - Method for determining human immunodeficiciency virus type 1 (HIV-1) hypersusceptibility to the protease inhibitor amprenavir (2009-06-30),

9. 7384734 - Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors (2008-06-10),

10. 7247439 - Method of evaluating a patient antibody response to envelope proteins of a virus (2007-07-24),

11. 7235356 - Methods of evaluating cell surface receptor binding of a patient derived population of viral envelope protein constructs (2007-06-26),

12. 7186506 - Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS (2007-03-06),

13. 7169551 - Methods of evaluating viral entry inhibitors using patient derived envelope protein constructs (2007-01-30),

14. 7138231 - Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS (2006-11-21),

15. 7097970 - Methods of evaluating viral entry inhibitors using patient derived envelope protein constructs (2006-08-29),

Title: Neil T Parkin: Innovator in HIV Research

Introduction

Neil T Parkin is an accomplished inventor based in Belmont, CA, with a remarkable portfolio of 22 patents to his name. His innovations primarily focus on advancements in HIV research, particularly in methods for understanding viral susceptibility and entry mechanisms.

Latest Patents

Among his latest patents, one notable invention is titled "Methods for determining hypersusceptibility of HIV-1 to non-nucleoside reverse transcriptase inhibitors." This invention is geared toward developing methods that identify hypersusceptibility of HIV-1 viruses to non-nucleoside reverse transcriptase inhibitors (NNRTIs) based on the viral genotypes. It primarily involves detecting mutations in the gene encoding reverse transcriptase, specifically looking for mutations at codons 65, 69, or 74, either alone or in combination with other mutations.

Another significant patent by Neil T Parkin is "Methods for evaluating viral receptor/co-receptor usage and inhibitors of virus entry using recombinant virus assays." This method aims to identify whether a particular compound can inhibit the entry of a virus into a cell. The procedure includes obtaining nucleic acid encoding a viral envelope protein from a patient infected with the virus and co-transfecting it into a cell alongside a viral expression vector that lacks the nucleic acid encoding the envelope protein. This innovative approach allows for measuring the effects of potential inhibitory compounds on viral entry.

Career Highlights

Neil has had a distinguished career, working with reputable companies such as Monogram Biosciences, Inc. and Aviron. His work at these institutions has significantly contributed to the progress in the field of virology and the development of antiviral therapies.

Collaborations

Throughout his career, Neil has collaborated with several notable individuals, including Christos J. Petropoulos and Wei Huang. These partnerships have fostered a collaborative environment that has been critical in advancing his research and innovations.

Conclusion

Neil T Parkin stands out as a prominent inventor in the domain of HIV research, with a significant record of patents that enhance our understanding of viral behaviors and treatment options. His work continues to inspire advancements in medical research and therapeutic development, underlining the importance of innovation in addressing global health challenges.

Profile summary based on public USPTO records.